Premium
Infliximab‐related weight gain in inflammatory bowel disease: associations and financial impacts
Author(s) -
Kaazan Patricia,
Tan Zhi,
Bednarz Jana,
Hughes Julie,
Grafton Rachel,
Andrews Jane M.
Publication year - 2020
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.14987
Subject(s) - medicine , infliximab , inflammatory bowel disease , weight change , cohort , weight gain , disease , weight loss , cohort study , gastroenterology , physical therapy , body weight , obesity
Association between tumour necrosis alpha inhibitors and weight gain has been reported. We examined weight change in our cohort of inflammatory bowel disease patients treated with infliximab (IFX) for over 12 months, its associations and financial implications. Two‐thirds of patients gained weight during the course of therapy. The mean change in weight after 12 months of IFX therapy was 3.3 (±6.5) kg.